CPNP Notification Errors That Delay EU Cosmetics Launches — What Regulation (EC) No 1223/2009 Actually Requires

Every week, we see the same pattern. A European cosmetics brand — sometimes a well-established one — submits their CPNP notification, gets their Responsible Person to confirm submission, and then discovers a compliance gap during a market surveillance check or a distributor audit. Not before launch. After.

The CPNP (Cosmetics Products Notification Portal) sits at the operational centre of EU compliance under Regulation (EC) No 1223/2009. Article 13 requires the Responsible Person to submit a notification to the portal before placing any cosmetic product on the EU market — and the obligation sounds straightforward until you’re actually working through the fields. That’s where the complexity surfaces. The portal accepts incomplete or inconsistent data without flagging an error. The problems only emerge later, and always at the worst possible moment.

Here is what we consistently see going wrong — and what to do before you hit submit.

What Article 13 of Regulation (EC) No 1223/2009 Actually Requires

Before covering errors, it’s worth being precise about the obligation itself. Article 13(1) of cosmetic regulation 1223/2009 requires the Responsible Person to submit the following information to the CPNP prior to EU market placement:

• The product category and product name in all languages relevant to the Member States of intended distribution
• The name and registered address of the Responsible Person
• The country of first EU market placement
• The INCI names of all substances, with CMR substances and nanomaterials flagged separately with their CAS and EC numbers
• A frame formulation reference, where applicable under Commission Decision 2013/674/EU
• Original labelling and a photograph of the packaging (where reasonably legible)

And that’s before the separate, additional six-month pre-notification obligation for nanomaterials under Article 16, which operates on a completely different compliance clock from the standard Article 13 notification.

The portal itself is managed by the European Commission’s Joint Research Centre and is accessible exclusively to Responsible Persons established within the EU. For non-EU brands — including those from North America or the UK post-Brexit — this means designating an EU-based Responsible Person before the portal can even be accessed. That designation needs to be documented in the Product Information File as well. It’s a step that sometimes gets treated as administrative when it is, in fact, foundational.

The Five CPNP Notification Errors We See Most Frequently

Error 1: Product Category Misclassification

This one surprises brands because it looks like the simplest field on the form. It isn’t.

The CPNP uses its own product category taxonomy — 24 main categories subdivided into functional subcategories. Brands routinely select a plausible-sounding category that turns out to be wrong. A hair serum making specific scalp-health claims may not sit cleanly in “hair conditioners.” A tinted moisturiser frequently gets miscategorised between “skin care” and “make-up,” without the applicant realising the distinction matters for how the safety assessment should be framed.

Wrong category doesn’t trigger an automated portal rejection. The CPNP will accept the notification regardless. But it creates a documented inconsistency between the PIF and the CPNP record — one that becomes very visible during a DGCCRF inspection or a distributor compliance audit in any of the 27 EU Member States. Correcting a category post-notification requires reopening the file, which delays confirmed compliance status for distributors who are waiting on documentation.

Error 2: INCI Nomenclature Errors and Missing CAS/EC Numbers

Article 13 requires ingredient listing in INCI nomenclature. But the CPNP goes further for specific ingredient types: it requires CAS (Chemical Abstracts Service) numbers and EC (European Community) numbers for any substance flagged as a CMR or as a nanomaterial.

What we see in practice: brands list ingredients under supplier trade names rather than INCI names, or work from outdated INCI designations on formulation sheets that haven’t been updated since the last batch reformulation. For complex botanical extracts — a glycerin-water extract of Centella asiatica leaf, for instance — the correct INCI designation depends on the extraction solvent ratio, the plant part used, and the physical form. Getting any of those details wrong at the CPNP level creates a discrepancy with the label and the PIF that is genuinely difficult to unwind post-launch without triggering a full product modification workflow.

The reference is the current version of the INCI dictionary maintained by the Personal Care Products Council. Using internal trade designations or legacy formulation terminology instead creates problems that compound over time.

Error 3: Missing the Article 16 Nanomaterial Pre-Notification — Six Months Out

This is the error that causes the most significant launch delays, and the one brands are least prepared for.

If your formulation contains any ingredient classified as a nanomaterial — whether listed in Annex VI (UV filters) or a novel non-listed nanomaterial you intend to use for the first time in EU cosmetics — Article 16 of Regulation (EC) No 1223/2009 requires a separate notification to the European Commission six months before the intended market placement date. This is independent of the standard Article 13 CPNP notification. The two obligations run in parallel, but the Article 16 clock starts six months earlier.

The EU’s operative nanomaterial definition applies to insoluble or biopersistent manufactured materials where 50% or more of particles in a number-size distribution have one or more external dimensions in the range 1–100 nm. Nano-form titanium dioxide in sunscreens is the most common example. It’s listed in Annex VI with specific permitted conditions and concentration limits, and it triggers the Article 16 pre-notification requirement. Suppliers should be providing particle size distribution data in their technical dossiers. But that data often doesn’t flow through reliably to the formulation team — particularly when the cosmetics chemist and the regulatory affairs team are working from different versions of the same ingredient specification sheet.

If you discover a nanomaterial in your formula after your planned launch date, you cannot accelerate the six-month clock. The launch moves. That’s a hard constraint, and it has caused real commercial damage to brands who assumed their sunscreen formula was compliant without confirming the nanoparticle status of every UV filter in the blend.

Error 4: Marking All 27 Member States as “On Market” Before Distribution Is Actually Live

The CPNP allows the Responsible Person to specify which EU Member States the product is available in. This field reads like an administrative checkbox. It isn’t.

Market surveillance authorities in each Member State use CPNP status data to prioritise inspections and product sampling. Brands that mark a product as “on market” across all 27 Member States immediately — before distribution is actually live — create an obligation to have compliant labelling (including legally required language-specific label translations) in markets they’re not yet serving. It also exposes the brand to enforcement queries from national competent authorities in countries where they have no distributor relationship, no local language labelling, and no practical ability to respond quickly.

The reverse problem is equally real: failing to update on-market status when entering a new Member State is a compliance gap in its own right. The practical discipline is to maintain the CPNP record to accurately reflect actual distribution footprint, updated at each new market entry — not set-and-forget at launch.

Error 5: Not Updating the Notification After Formulation or Label Changes

Article 13 of EC regulation 1223/2009 requires the Responsible Person to update the CPNP notification if any of the submitted information changes. This obligation is not optional, and the portal does not prompt you. There is no automated reminder. The update has to be initiated manually.

In practice, brands reformulate regularly — because of ingredient supply disruptions, because of new restrictions under Annexes II or III (Commission Regulations amending these annexes are published several times per year), because a raw material supplier changes their process in a way that alters the INCI composition of a blend, or because a claims adjustment changes the labelling photographs attached to the notification.

Every one of those changes triggers an update obligation. We’ve worked with brands that operated for 12 to 18 months on an outdated CPNP record after a quiet mid-cycle reformulation, discovering the gap only during a third-party compliance audit before entering a new market. At that point, the update must be filed with an explanation of the lag — an uncomfortable conversation, and one that raises questions about the integrity of the broader quality system.

A Pre-Submission Checklist: Catch It Before You Log In

The CPNP offers no pre-submission validation beyond basic field completion. All quality control has to happen before you open the portal. At minimum, cross-reference the following against your Product Information File before submission:

1. INCI list on the CPNP notification matches, character for character, the INCI list on the label and in the cosmetic safety assessment within the PIF
2. Product category code is consistent with the product function described in the safety assessment — not just a “close enough” selection
3. Nanomaterial screening has been completed using supplier technical dossiers, with particle size distribution data reviewed for every UV filter, pigment, and mineral ingredient in the formula
4. CMR substance review is documented: any substance appearing on the REACH Candidate List or classified under CLP Regulation as CMR Category 1A or 1B has been assessed for permissibility under Annexes II and III of Regulation (EC) No 1223/2009
5. Distribution footprint in the Member State on-market flags reflects actual launch territory, with a process documented for updating it at each subsequent market entry

If your Responsible Person is a third-party compliance service — which is standard for non-EU brands using an EU RP designation — confirm explicitly in writing who holds the obligation for updating the notification after any product change. This handoff is where CPNP records most often stall and fall out of sync with the actual product.

Getting the CPNP notification right is not the entirety of what cosmetic regulation 1223/2009 requires. It sits within a broader framework: the full Product Information File, the cosmetic safety report from a qualified safety assessor, GMP documentation to ISO 22716, and ongoing cosmetovigilance with serious undesirable effect (SUE) reporting. But the CPNP record is the most visible external signal of your compliance status — the first document a market surveillance authority, a distributor’s compliance team, or a customs officer in a new market will reference.

Treat it as a living document. Update it when formulations change, when labelling changes, and when distribution changes. The brands that stay out of trouble in EU markets are the ones who build that discipline into their post-launch workflow from day one — not the ones scrambling to reconcile records six months after a quiet reformulation.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Care Europe | VP Operations, Qalitex. Learn more about our team

Talk to our team about EU market entry. Contact us

Related from our network

• EU Cosmetics Testing to ISO 17025 Standards — Qalitex Laboratories provides ISO 17025-accredited testing for cosmetic safety assessments, including INCI verification, heavy metals panels, and microbiological release testing for EU market compliance.
• Health Canada Cosmetics Notification for European Brands — Androxa supports European cosmetics manufacturers navigating Health Canada’s Cosmetic Regulations, including ingredient notification and bilingual labelling requirements for the Canadian market.